In neurodegenerative disorders, abnormally hyperphosphorylated and aggregated tau accumulates intracellularly, a mechanism which is thought to induce neuronal cell death. Methylene blue, a type of phenothiazine, has been reported to inhibit tau aggregation in vitro. However, the effect of methylene blue in vivo has remained unknown. Therefore, we examined whether methylene blue suppresses abnormal tau accumulation using P301L tau transgenic mice. At 8 to 11 months of age, these mice were orally administered methylene blue for 5 months. Subsequent results of Western blotting analysis revealed that this agent reduced detergent-insoluble phospho-tau. Methylene blue may have potential as a drug candidate for the treatment of tauopathy.
Citation: Hosokawa M, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, et al. (2012) Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice. PLoS ONE 7(12): e52389. doi:10.1371/journal.pone.0052389
Editor: Andrea C. LeBlanc, McGill University, Canada
Received: June 12, 2012; Accepted: November 14, 2012; Published: December 20, 2012
Copyright: © 2012 Hosokawa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was partially supported by the Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research (C), grant number 21591536 to HA and 24591738 to M. Hosokawa. The additional part of the funding of the authors′ study has come from institute budget. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
In neurodegenerative disorders such as Alzheimer’s disease, corticobasal degeneration, and supranuclear palsy, the microtubule–associated protein tau is abnormally phosphorylated and redistributed into paired helical filaments (PHFs) forming neurofibrillary tangles, a process that correlates with pyramidal cell destruction and dementia. Abnormal tau accumulation is characterized by hyperphosphorylation, conformational change and aggregation with changes in solubility.
Wischik et al. have identified a nonneuroleptic phenothiazine which reverses the proteolytic stability of protease-resistant PHFs by blocking tau-tau binding through the repeat domain . Moreover, phenothiazines, including methylthioninium chloride (methylene blue (MB)), polyphenols and porphyrins, inhibited heparin-induced tau filament formation in vitro . Based on these results, tau aggregation inhibitors are considered to be strong candidates for the treatment of tauopathy.
TauRx Pharmaceuticals recently announced the completion of MB phase II clinical trials. They conducted MB dosing and efficacy studies involving 321 people with mild to moderate Alzheimer’s disease. Over a 50-week period, the cognitive decline of those on the drug appeared to be 81% slower than those taking a placebo. These results were presented at a conference  but have not been published. Currently, a large-scale phase III trial is in planning .
To date, there are two reports on the effect of MB on tau aggregation in vivo. In one study, MB did not alter abnormal tau phosphorylation and failed to inhibit tau-dependent neuronal cell toxicity in zebrafish . The other study employed a distinct tau transgenic mouse line and mice received a 2–3-week treatment with oral MB. In this latter study, MB acted as a tau aggregation inhibitor. Although, these findings have been described in brief in a conference abstract, the details are unavailable .
More recently, Congdon et al. demonstrated that MB could induce autophagy in primary neurons, organotypic slice cultures and tau transgenic mice (JNPL3) . They also showed a 2 week oral administration of MB attenuated the total tau levels in the absence of significant changes in sarkosyl-insoluble tau levels.
In the present study, we investigated whether MB could reduce abnormal tau accumulation by carrying out long-term oral administration of MB using tau transgenic mice with the P301L mutation as a tauopathy model. Our results suggested that oral intake of MB could be a potential treatment for tauopathy.
Materials and Methods
This study was carried out in strict accordance with the recommendations provided in the Guide for the Care and Use of Laboratory Animals of the Ministry of Health, Labour and Welfare of Japan and the Ministry of Education, Culture, Sports, Science and Technology of Japan. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Tokyo Metropolitan Institute of Medical Science (Permit Numbers: 22–23 and 11-028). All experiments were performed under sodium pentobarbital anesthesia and every effort was made to minimize suffering.
P301L tau transgenic mice (JNPL3)  were purchased from Taconic (USA) via IBL (Japan). The experiments utilized 44 female hemizygote tau mice. The mice were reared in the animal facility of Tokyo Metropolitan Institute of Medical Science under standard conditions at 24±2°C and were maintained on a commercial diet supplied ad libitum.
The transgenic mice  aged 8–11 months were divided into 3 groups: the first group (14 mice) was given water alone, the second group (15 mice) was given water containing 2 µg/ml MB and the third group (15 mice) was given water containing 6 µg/ml MB. All were maintained on their respective regimens for 5 months. The daily MB intake was estimated to be about 0.3 or 1 mg/kg/day per mouse, on the assumption that a mouse weighs 30 g and takes in 5 ml of water a day.
At the end of the experimental period, mice were sacrificed under quick anesthesia with 200 mg/kg body weight of sodium pentobarbital delivered intraperitoneally and their brains were quickly removed. Brains of each group were cut along the sagittal plane and the left hemisphere was frozen and stored at −80°C for biochemical analyses. The right hemisphere was fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 48 hours in the cold. Brain blocks were then transferred to a maintenance solution of 15% sucrose in 0.01 M phosphate-buffered saline (PBS), pH 7.4.
Analysis of Tau Deposition
Deposition of tau was analyzed using immunohistochemical staining with AT8 antibody (recognizes phosphorylation at both serine 202 and threonine 205) and MC-1 antibody. Biotinylation of MC-1 antibody was performed using a Zenon Mouse IgG Labeling Kit (Molecular Probes, Inc. Eugene, OR, USA) according to the manufacturer’s instructions. For immunohistochemistry, sagittal sections were cut serially on a freezing microtome at 30 µm thickness, collected in the maintenance solution, and immunostained as free-floating sections. Following a pretreatment with 0.5% H202 for 30 min to eliminate endogenous peroxidase activity, sections were incubated for 72 hours with AT8 antibody (Biotinylated-AT8, 1:1,000, Innogenetics, Ghent, Belgium) or overnight with biotinylated MC-1 antibody (1:100, a generous gift of Dr. Davies)  diluted in PBS containing 0.3% Triton X-100 (PBS-Tx). The antibody labeling was visualized by incubation with avidin-biotinylated horseradish peroxidase (HRP) complex (ABC Elite, 1:1,000, Vector Laboratories, Burlingame, CA, USA) for 3 hours, followed by incubation with a solution containing 0.01% 3,3′-diaminobenzidine (DAB), 1% nickel ammonium sulfate, 0.05 M imidazole and 0.00015% H202 in 0.05 M Tris-HCl buffer, pH 7.6. Counter nuclear staining was performed with Kernechtrot stain solution (Merck, Darmstadt, Germany). The sections were then rinsed with distilled water, mounted on glass slides, treated with Xylene, and coverslipped with Entellan (Merck). Photographs were taken with an Olympus VS120-S5 (Olympus, Tokyo, Japan) or a BX51 microscope (Olympus).
Sequential Fractionation of Brain Extracts
Frozen left hemispheres (approximately, 0.2 g) were homogenized in 10 volumes of buffer H (10 mM Tris-HCl, pH 7.5, 0.8 M NaCl, 1 mM ethylene glycol bis-N, N, N’, N’-tetraacetic acid, 1 mM dithiothreitol). The hemisphere included the olfactory bulb, cerebral cortex, striatum, thalamus, hypothalamus, cerebellum, midbrain, pons, medulla oblongata and the upper part of the spinal cord. The method used for sequential fractionation of brain extracts was originally described by Greenberg et al. . Briefly, the brain homogenate was centrifuged at 100,000×g for 20 min at 4°C, and the supernatants were collected as the Tris-soluble fraction. The resultant pellet was homogenized in 10 volumes of buffer H, followed by an incubation for 30 min at 37°C with 1% Triton X-100. The homogenate was then centrifuged at 100,000×g for 20 min at 4°C. The Triton X-100 insoluble pellet was sonicated in 5 volumes of buffer H containing 1% sarkosyl and centrifuged at 100,000×g for 20 min at 4°C. The pellet was then sonicated in 1 volume of SDS-PAGE sample buffer.
For immunoblotting, brain extracts from the tau mice were boiled for 5 minutes with SDS-PAGE sample buffer (60 mM Tris-HCl, pH 6.8, containing 2% SDS, 10% glycerol, 0.025% bromophenol blue and 5% mercaptoethanol) and loaded onto a 10% acrylamide minigel. Loaded samples were electrophoresed for 45 minutes at 200 V with molecular weight markers (Bio-Rad, Hercules, CA, USA). Electrophoresed proteins were transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA) for 60 minutes at 200 mA. The printed membranes were blocked with 3% gelatin for 1 hour and then incubated in a primary antibody solution (HT7, 1:3,000, Innogenetics, AT8, 1:3,000, Innogenetics, or anti-α-tubulin, 1:10,000, Sigma, St. Louis, MO, USA) overnight at room temperature. Following incubation with a secondary antibody (1:20,000, Bio-Rad), immunoreactivity was detected by the chemiluminescence method using an ECL plus Western Blotting Detection Kit (GE Healthcare UK Ltd., Buckinghamshire, England) or SuperSignal West Dura Extended Duration Substrate (Pierce, Rockford IL, USA) and was visualized with LAS-3000 (Fujifilm, Tokyo, Japan). For quantitative measure of band intensity, α-tubulin was used as an internal control for protein concentration.
The data are presented as medians (interquartile range) [range]. The significance of difference between values was estimated by means of Kruskal-Wallis analysis of variances with post hoc Steel’s method. P<0.05 was considered to indicate a statistically significant difference.
To investigate the effect of methylene bule on tau accumulation, P301L tau transgenic mice were administered MB for 5 months starting at 8–11 months of age. Brains were then collected and sequential protein extraction and immunoblotting were performed (Figs. 1, 2, 3, 4). Total tau in the Tris-soluble fraction was detected by HT7 antibody (Fig. 1A), and there were no prominent differences among the three groups by quantitative analysis of band intensities, which was normalized with α-tubulin (Fig. 1B). Phosphorylated tau in the Tris-soluble fraction was also detected by AT8 antibody (Fig. 2A). The data were compared with the AT8 band intensity, which was normalized with α-tubulin (Fig. 2B) or with the total tau (HT7) band intensity (Fig. 2C). There were also no significant differences in phosphorylated tau in the Tris-soluble fraction among the three groups (Figs. 2B and 2C).
(A) Immunoblotting analysis was visualized using HT7 antibody for the Tris-soluble fraction. The numbers indicate individual mice: 1–15, MB 1 mg/kg/day group; 16–30, MB 0.3 mg/kg/day group; and 31–44, water only group. Molecular weight markers are shown on the right (kDa). For quantitative measure of band intensity, α-tubulin was used as an internal control for protein concentration. (B) A comparison of the relative total tau (HT7) expression levels of the MB-treated groups and the water only group. The data were compared with the HT7 band intensity, which was normalized with α-tubulin. The central lines indicate medians and the vertical lines represent 25th and 75th percentiles. a.u., arbitrary unit. N.S., no significant difference.
(A) Immunoblot analysis was visualized using AT8 antibody for the Tris-soluble fraction. The numbers indicate individual mice: 1–15, MB 1 mg/kg/day group; 16–30, MB 0.3 mg/kg/day group; and 31–44, water only group. Molecular weight markers are shown on the right (kDa). P, positive control (P301L tau transgenic mouse, 20 month-old female). (B) A comparison of relative phosphorylated tau (AT8) expression levels of the MB-treated groups and the water only group. The data were compared with the AT8 band intensity, which was normalized with α-tubulin. (C) A comparison of the relative phosphorylated tau (AT8)/total tau (HT7) levels of the MB-treated groups and the water only group. The data were compared with the AT8 band intensity, which was normalized with the total tau (HT7) band intensity. The central lines indicate medians and the vertical lines represent 25th and 75th percentiles. a.u., arbitrary unit. N.S., no significant difference.
Phosphorylated tau and total tau in the sarkosyl-insoluble fraction were visualized again by Western blotting using HT7 antibody (Fig. 3A) and AT8 (Fig. 4A), respectively. The HT7 (Fig. 3B) and AT8 (Fig. 4B) band intensities were measured. Then, we compared the AT8 band intensity normalized by the total tau (HT7) band intensity and were expressed as medians (interquartile range) [range]. The AT8/HT7 ratio was 0.47 (0.40–0.53) [0.09–0.85] (n = 15) in the MB group given 1 mg/kg/day, 0.70 (0.62–0.82) [0.19–1.12] (n = 15) in the MB group given 0.3 mg/kg/day, and 0.74 (0.65–0.86) [0.60–1.04] (n = 14) in the group given water alone (Fig. 4C). The Kruskal-Wallis test followed by Steel’s multiple comparison test was used for statistical analyses, and there was a significant difference between the group given MB 1 mg/kg/day and the group given water alone (P<0.001). There was no significant difference between the 0.3 mg/kg/day group and the water only group (P = 0.422). Immunoblotting analysis revealed that the level of abnormally phosphorylated tau accumulation was decreased in the P301L tau mice given MB as compared with the P301L tau mice given water alone.
(A) Immunoblot analysis was visualized using HT7 antibody for the sarkosyl-insoluble fraction. The numbers indicate individual mice: 1–15, MB 1 mg/kg/day group; 16–30, MB 0.3 mg/kg/day group; 31–44, water only group. Molecular weight markers are shown on the right (kDa). (B) A comparison of relative total tau (HT7) expression levels in the sarkosyl-insoluble fraction of the MB-treated groups and the water only group. The data were compared with the HT7 band intensity. The central lines indicate medians and the vertical lines represent 25th and 75th percentiles. a.u., arbitrary unit.
(A) Immunoblotting analysis was visualized using AT8 antibody for the sarkosyl-insoluble fraction. The numbers indicate individual mice: 1–15, MB 1 mg/kg/day group; 16–30, MB 0.3 mg/kg/day group; and 31–44, water only group. Molecular weight markers are shown on the right (kDa). P, positive control (P301L tau transgenic mouse, 20 month-old female). (B) A comparison of relative AT8 expression levels of the MB-treated groups and the water only group. The data were compared with the AT8 band intensity. (C) A comparison of relative phosphorylated tau (AT8)/total tau (HT7) levels of the MB-treated groups and the water only group. The data were compared with the AT8 band intensity, which was normalized with the total tau (HT7) band intensity. The central lines indicate medians and the vertical lines represent 25th and 75th percentiles. P<0.01 was considered to represent a statistically significant difference. a.u., arbitrary unit. N.S., no significant difference.
Analysis of Tau Deposition
A weak AT8 immunoreaction was observed only in the spinal cord, medulla oblongata and pons of the mice with a low AT8/HT7 ratio (Fig. 5A). On the other hand, AT8-positive cells were seen in the spinal cord, medulla oblongata, cerebellar nuclei, pons, midbrain, hypothalamus and primary motor cortex of mice with a high AT8/HT7 ratio (Fig. 5B). Immunohistochemical staining with a conformational antibody, MC-1, which recognizes aggregated tau showed that MC-1-positive neurons and cellular processes were seen in the motor cortex, hypothalamus and pons (Fig. 6). However, MC-1-positive neurons and cellular processes in these areas of mice with a low AT8/HT7 ratio were significantly fewer than those in mice with a high AT8/HT7 ratio.
(A) An AT8 immunoreaction was observed only in spinal cord, medulla oblongata and pons of a mouse with a low AT8/HT7 ratio. (B) AT8-positive cells were seen in spinal cord, medulla oblongata, pons, midbrain, hypothalamus and cerebral cortex of a mouse with a high AT8/HT7 ratio. Each insert shows the cerebral cortex of the mouse brain.
MC-1-positive neurons and cellular processes were seen in the motor cortex (A and B), prepotic area (C and D), posterior hypothalamus (E and F) and pons (G and H). A, C, E, G, mouse with a low AT8/HT7 ratio; and B, D, F, H, mouse with a high AT8/HT7 ratio. The calibration bar in H applies to all photomicrographs (50 µm).
Cases of dementia including AD have been increasing in number in recent years, and discovering effective drugs for treating these diseases must be facilitated. Developing a novel drug for the treatment of AD is a time-consuming process and a better approach might be through screening chemical compounds or drugs which are already available. Consequently, we evaluated MB inhibition of abnormal tau accumulation using a tauopathy mouse model, since MB had been shown to be a protein aggregation inhibitor in vitro  as well as more recently in cells .
MB was found to have an inhibitory effect on tau aggregation in vitro – and to act as a tau aggregation inhibitor in a cellular model as well as in transgenic mice . However, in the latter case, only an abstract was published on these findings and the details were unavailable. More recently, Congdon et al. reported that MB induced autophagy and attenuated tauopathy in vitro and in vivo . They administrated MB (0.02, 2, and 20 mg/kg) to tau transgenic mice (JNPL3) by oral gavage 5 days a week for 2 weeks and performed immunoblotting for total human tau and sarkosyl-insoluble fractions. There was a significant reduction in the levels of total tau and phosphorylated tau in their MB-treated mice, however, the levels of sarkosyl-insoluble tau were unchanged . In the present study, the immunoblotting data revealed that phosphorylated tau was decreased in the sarkosyl-insoluble fraction after MB administration (Fig. 4). In both soluble and insoluble fractions, the amount of total tau did not differ among the three groups (Fig. 1 and 3), suggesting that the MB administration did not affect the transgenic tau expression but reduced the aggregation of phosphorylated tau. Moreover, immunohistochemical staining demonstrated that MB inhibited the spread of abnormal tau deposition from the brain stem to the cerebral cortex (Fig. 5 and 6). These immunohistochemistry findings supported the results obtained by immunoblotting.
The results of this study may agree with those by Congdon et al. in that the MB treatment reduced phosphorylated tau levels . They also found reduction in the total tau levels in the total but not sarkosyl-insoluble brain fractions. While we did not examine the total brain fractions, we did not see significant changes in the levels of both soluble and insoluble tau between the MB and water treated groups. The reason for such a difference remains unknown, but it might be noteworthy that the duration of MB treatments was quite different between the two studies; we administrated MB 7 days a week for 5 months whereas they did 5 days a week for 2 weeks.
In a study by Medina et al., 0.025% MB was supplied in food to 3×Tg AD mice from 6 to 10 months of age. These mice subsequently showed reduced Aβ levels (soluble Aβ40 and Aβ42) and were rescued from an early cognitive deficit by an increase in proteasome activity . MB improved learning and memory in these mice and the MB treatment did not affect mitochondrial function or tau pathology. In contrast, Necula et al. demonstrated that MB inhibited Aβ oligomerization by promoting fibril formation in vivo .
MB did not affect abnormal tau phosphorylation in a tau transgenic zebrafish model . It also failed to inhibit tau and polyglutamine-protein-dependent toxicity in zebrafish, although polyglutamine aggregation was dramatically reduced. These negative results led to the conclusion that an insufficient dose of MB had been used in vivo . Fertilized eggs of tau transgenic fish were cultured in a buffer containing 10−5% MB. However, this transgenic model was not suitable for in vivo analysis of protein aggregation and deposition. Recently, Yamashita et al. reported that MB prevented deposition of TDP-43 in a cell culture model based on ectopic overexpression of TDP-43 . These findings suggested that MB would have an anti-aggregation effect on other neurodegeneration-associated proteins.
Recent reports have indicated that MB affects the brain in many ways: it inhibits butyrylcholinesterase activity , inhibits noradrenalin re-uptake , reduces cGMP and nitric oxide , increases extracellular levels of serotonin (5-HT) in rat brain , and modulates the functions of AMPA/kainate and NMDA-type ionotropic glutamate receptors –. The beneficial effect on cognitive function observed in AD patients after MB administration may be in part attributable to its influence on the cholinergic, serotonergic and glutamatergic systems . MB also improves mitochondrial respiration by shuttling electrons to oxygen in the electron transport chain, and corrects perturbations in mitochondrial metabolism induced by mutagens –.
Our study suggests that MB has disease-modifying activity in targeting tauopathy involving AD. The administration of MB carried out here was very simple and could easily be applied in screening other compounds for targeting tauopathy. MB could be a leading candidate, and some MB derivatives might be exploited to develop even stronger inhibition of tau aggregation.
MB has already been used for the treatment of methemoglobinemia –, septic shock –, and Plasmodium infection (malaria) –, which may expedite its quick approval as a potential therapeutic agent for tauopathy. While the mechanism involved remains unknown, our data suggest that administration of methylene blue might reduce abnormal tau accumulation. Finally, we did not study pharmacokinetics of MB. Congdon et al.  demonstrated the brain concentration of MB increased in parallel with the given doses, but this is an issue that also needs futher, more detailed exploration.
We thank Dr. P. Davies for providing MC-1 antibody. We thank Ms. Hiromi Kondo for immunohistochemical staining and Ms. Erika Arakawa for technical assistance and animal care. We also thank Dr. William Campbell and Catherine Campbell for editing of the manuscript.
Conceived and designed the experiments: M. Hosokawa TA HA. Performed the experiments: M. Hosokawa MM-S. Analyzed the data: M. Hosokawa MM-S TN MY HA M. Hasegawa. Contributed reagents/materials/analysis tools: MM-S TN M. Hasegawa. Wrote the paper: M. Hosokawa TA HA.
- 1. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93: 11213–11218. doi: 10.1073/pnas.93.20.11213
- 2. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, et al. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280: 7614–7623. doi: 10.1074/jbc.m408714200
- 3. Wischik CM, Bentham P, Wischik DJ, Seng KM (2008) Tau aggregation inhibitor (TAI) therapy with Rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's & Dementia 8: T167. doi: 10.1016/j.jalz.2008.05.438
- 4. Gravitz L (2011) Drugs: a tangled web of targets. Nature 475: S9–11. doi: 10.1038/475s9a
- 5. van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C (2010) Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis 39: 265–271. doi: 10.1016/j.nbd.2010.03.023
- 6. Harrington C, Rickard JE, Horsley D, Harrington KA, Hindley KP, et al. (2008) Methylthioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease. Alzheimer's & Dementia 4: T120–T121. doi: 10.1016/j.jalz.2008.05.259
- 7. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, et al. (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8: 609–622. doi: 10.4161/auto.19048
- 8. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25: 402–405.
- 9. Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol 22: 521–526. doi: 10.1002/ana.410220412
- 10. Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 87: 5827–5831. doi: 10.1073/pnas.87.15.5827
- 11. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, et al. (2009) Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 583: 2419–2424. doi: 10.1016/j.febslet.2009.06.042
- 12. Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21: 140–149. doi: 10.1111/j.1750-3639.2010.00430.x
- 13. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, et al. (2007) Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 46: 8850–8860. doi: 10.1021/bi700411k
- 14. Kucukkilinc T, Ozer I (2007) Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes. Arch Biochem Biophys 461: 294–298. doi: 10.1016/j.abb.2007.02.029
- 15. Chies AB, Custodio RC, de Souza GL, Correa FM, Pereira OC (2003) Pharmacological evidence that methylene blue inhibits noradrenaline neuronal uptake in the rat vas deferens. Pol J Pharmacol 55: 573–579.
- 16. Heiberg IL, Wegener G, Rosenberg R (2002) Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134: 479–484. doi: 10.1016/s0166-4328(02)00084-0
- 17. Gonzalez-Lima F, Bruchey AK (2004) Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem 11: 633–640. doi: 10.1101/lm.82404
- 18. Wrubel KM, Riha PD, Maldonado MA, McCollum D, Gonzalez-Lima F (2007) The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav 86: 712–717. doi: 10.1016/j.pbb.2007.02.018
- 19. Visarius TM, Stucki JW, Lauterburg BH (1997) Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 412: 157–160. doi: 10.1016/s0014-5793(97)00767-9
- 20. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, et al. (2008) Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 22: 703–712. doi: 10.1096/fj.07-9610com
- 21. Kristiansen JE (1989) Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. Dan Med Bull 36: 178–185.
- 22. Mansouri A, Lurie AA (1993) Concise review: methemoglobinemia. Am J Hematol 42: 7–12. doi: 10.1002/ajh.2830420104
- 23. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD (1992) Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med 18: 309–311. doi: 10.1007/bf01706481
- 24. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, et al. (1995) Methylene blue administration in septic shock: a clinical trial. Crit Care Med 23: 259–264. doi: 10.1097/00003246-199502000-00010
- 25. Schirmer RH, Coulibaly B, Stich A, Scheiwein M, Merkle H, et al. (2003) Methylene blue as an antimalarial agent. Redox Rep 8: 272–275. doi: 10.1179/135100003225002899
- 26. Rengelshausen J, Burhenne J, Frohlich M, Tayrouz Y, Singh SK, et al. (2004) Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 60: 709–715. doi: 10.1007/s00228-004-0818-0